Flow cytometric analysis of CD137 expression on C57BL/6 mouse splenocytes treated overnight with 3 μg/ml Concanavalin A. C57BL/6 mouse splenocytes treated overnight with 3 μg/ml Concanavalin A (right panel) or untreated (left panel) were stained with Brilliant Violet 421™ Rat Anti-Mouse CD25 Antibody and SDT Biotin Rabbit Anti- Mouse CD137 Antibody at 2 μl/test followed by Sav-iFluor 488. Flow cytometry and data analysis were performed using Agilent NovoCyte Quanteon and FlowJo™ software.
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | CD137 |
| Synonyms | Tumor necrosis factor receptor superfamily member 9; 4-1BB ligand receptor; T-cell antigen 4-1BB; Ila; Ly63; Tnfrsf9 |
| Immunogen | Recombinant Protein |
| Location | Cell membrane |
| Accession | P20334 |
| Clone Number | S-547-3 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Isotype Control | S0B8273 |
| Application | FCM |
| Reactivity | Ms |
| Positive Sample | C57BL/6 mouse splenocytes treated overnight with 3μg/ml Concanavalin A |
| Purification | Protein A |
| Concentration | 0.5 mg/ml |
| Conjugation | Biotin |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, 0.09% sodium azide |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1μg per million cells in 100μl volume | Ms |
Background
CD137, a member of the tumor necrosis factor (TNF) receptor family, is a type 1 transmembrane protein, expressed on surfaces of leukocytes and non-immune cells. CD137 is only expressed on the cell surface after T cell activation. When T cells are activated by Antigen Presenting Cells (APCs), CD137 becomes embedded in CD4+ and CD8+ T cells. CD137 is a costimulatory molecule functioning to stimulate T cell proliferation, dendritic cell maturation, and promotion of B cell antibody secretion. CD137 is also involved in cancer having been found upregulated in cancerous cell lines. CD137/ligand stimulation has been found to lead to stronger anti-tumor responses due to cytotoxic T cell activation and is being examined as a possible anticancer therapy.
Picture
Picture
FC
